Neonc Technologies Holdings Inc.

Calabasas, CA

UEI
XLZVF5LX5JM8
CAGE
18MG9
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
23975 Park Sorrento #205, Calabasas, CA 91302, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of NEO212, a novel oral drug for the treatment of acute myeloid leukemia R41CA271879 National Cancer Institute (NIH) $399,998
Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas - despite important advances in… R42CA246902 National Cancer Institute (NIH) $1,007,612

Quick answers

Is Neonc Technologies Holdings Inc. registered in SAM.gov?

Yes. Neonc Technologies Holdings Inc.'s SAM.gov registration is active through January 26, 2027.

What is Neonc Technologies Holdings Inc.'s most recent federal award?

Neonc Technologies Holdings Inc.'s most recent federal grant award is Development of NEO212, a novel oral drug for the treatment of acute myeloid leukemia (R41CA271879), from National Cancer Institute (NIH), on August 7, 2025.

On GovTribe

See Neonc Technologies Holdings Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login